1. Scrip

US FDA cites Bayer for Yaz TV commercial violations

 
• By Sue Sutter

Two television commercials for[C#198600358:Bayer] Healthcare's Yaz (drospirenone plus ethinylestradiol) broaden the oral contraceptive’s indication, overstate its efficacy and minimise risks, the US FDAhas said in a warning letter.

Two television commercials forBayer Healthcare's Yaz (drospirenone plus ethinylestradiol) broaden the oral contraceptive’s indication, overstate its efficacy and minimise risks, the US FDAhas said in a warning letter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapeutic Category

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.